20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
Colorectal cancer is the result of a process taking several years and basically consists of the transformation of normal cells into cancer cells; in this stage (called the prodromal phase), people are apparently healthy and totally asymptomatic, but several factors that are actively driving this transformation process become evident with the appearance of a precancerous lesion (i.e., adenomatous polyp). HELIXAFE is the pioneering AI-based prevention program that allows BIOSCIENCE GENOMICS to intercept the modifiable physio-pathological conditions that lead to cancer (the cancer drivers) by monitoring genomic instability, systemic inflammation, gut microbiome imbalance, and immune system deficiency.
Once intercepted, HELIXAFE monitors the actionable cancer drivers, providing useful feedback on the cancer prodromal condition progression and on the effectiveness of the strategies in place to reduce the risk of cancer development (e.g., the use of drugs, vitamins, or other agents). The breakthrough innovation at the core of our monitoring program relies on the capacity unique to HELIXAFE to evaluate the progressive accumulation of somatic mutations. This condition is a key indicator of the DNA Damage Response (DDR) malfunctioning and/or of the tumor suppressor gene failure, and it leads to genomic instability, which is the primary cancer driver. Through the integrated analysis of data from the assessment of physiological conditions (genetic instability, systemic inflammation, intestinal bacterial imbalance, and immune system imbalance) in people at risk and without evident marks of developing colorectal cancer, our AI-based tool can create a risk profile of each individual. This can initially have a preventive value and then become predictive over time thanks to the precision acquired by the AI over time. In addition, the tool can suggest using biological chemo-preventive agents (e.g., natural, synthetic, biological) to treat the pathophysiological conditions driving the development of the solid tumor. HELIXAFE provides the breakthrough concept of cancer driver interception, enabling the detection of genomic instability in somatic cells several years before the disease occurrence.
Cancer arises from a transformation process of healthy cells into cancerous cells over a period of years or even decades (prodromal phase), in which people are apparently healthy and totally asymptomatic. In this phase, several factors, such as genomic instability, chronic inflammation, immune system imbalance, and bacterial imbalance, actively drive the cell transformation process. To date, these cancer drivers can only be intercepted by HELIXAFE. However, our protocol does not stop with the simple interception of these drivers: we have a monitoring and managing plan for these conditions to cure cancer way before its occurrence. The revolutionary aspect of our innovation is that it allows intervention before cancer onset, a disruptive new vision in the battle against cancer.
HELIXAFE shifts the focus of cancer prevention from early-stage cancer detection to cancer driver interception, a drastic change of paradigm for the entire society. Therefore, HELIXAFE is not a cancer screening test; it does not evaluate cancer genetic predispositions (e.g., BRCA 1-2), and it is not a cancer early detection test. By performing periodic monitoring of somatic mutations through sequencing of the cell-free circulating DNA, HELIXAFE monitors genomic instability, thus intercepting solid cancer in its prodromal phase, and will be able to suggest personalized chemo-preventive measures to adopt to reduce the risk of cancer development. The solution provided by HELIXAFE aims to anticipate early detection using effective prevention measures, going far beyond the so-called “primary prevention”. In addition, the AI algorithm will be optimized and perfected by the continuous feeds provided by periodic monitoring data.
